Joshua Welsh,
Research Fellow,
National Cancer Institute (NCI), NCI
Dr Welsh is currently a Research Fellow within the Translational Nanobiology Section at the National Institutes of Health. Dr Welsh received his PhD from the University of Southampton where he worked with Thermo Fisher Scientific to develop a small particle flow cytometer and developed light scatter calibration methods. Since joining the Translational Nanobiology Section, his research has focused on developing a high-throughput, scalable, clinical pipeline for characterizing extracellular vesicles for their use as clinical biomarkers. This work has involved developing assays, standalone software, standardization methods, and multidimensional data analyses. Josh is a member-at-large of the ISEV Executive Board, associate editor of current protocols in cytometry, chair of the ISEV Rigor and Standardization: EV Reference Materials Task Force, Member of ISAC data committee, member of ISAC-ISEV-ISTH EV Flow Cytometry Working Group, and an ISAC Marylou Ingram scholar.
Profiling EV Subsets and Cargo to Enable Adaptive Tumor- and Immuno-therapies
Tuesday, 26 September 2017 at 17:30
Add to Calendar ▼2017-09-26 17:30:002017-09-26 18:30:00Europe/LondonProfiling EV Subsets and Cargo to Enable Adaptive Tumor- and Immuno-therapiesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
Exosomes and small viruses fall below the detection limits of conventional flow cytometers, which has limited ways to identify, sort, and study, distinct subsets of EVs and other nanoparticles as single particles. In order to maximize information and material that can be obtained with high speed, high resolution flow cytometers we have developed nanoscale Fluorescence Associated Cytometric Sorting (nanoFACS). We have demonstrated nanoFACS to be capable of detecting tumor-cell derived EVs with specific tumor antigens, such as Prostate Specific Membrane Antigen (PSMA), with fluorescence and scattered light parameters, as well as being capable of sorting two distinct HIV strains (85-125 nm) to >95% purity. The development of our nanoFACS method provides a unique way to analyze and sort functional EV- and viral-subsets, while preserving vesicular structure, surface protein specificity, and RNA cargo activity.
Add to Calendar ▼2017-09-26 17:30:002017-09-26 18:30:00Europe/LondonProfiling EV Subsets and Cargo to Enable Adaptive Tumor- and Immuno-therapiesExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
